Illumina, Inc. $ILMN Stock Holdings Increased by Capital International Ltd. CA

Capital International Ltd. CA boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 16.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,849 shares of the life sciences company’s stock after purchasing an additional 9,258 shares during the quarter. Capital International Ltd. CA’s holdings in Illumina were worth $6,159,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust increased its holdings in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the period. Quent Capital LLC acquired a new stake in Illumina in the 3rd quarter valued at approximately $29,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina during the 3rd quarter worth $33,000. Mather Group LLC. acquired a new position in shares of Illumina during the third quarter valued at $46,000. Finally, Evelyn Partners Investment Management LLP raised its stake in shares of Illumina by 4,927.3% during the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ILMN. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Canaccord Genuity Group boosted their price target on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Guggenheim raised their price objective on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $129.69.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $124.28 on Tuesday. The business has a fifty day simple moving average of $134.17 and a 200-day simple moving average of $119.55. The stock has a market cap of $19.00 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 2.38 and a beta of 1.45. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the company earned $0.95 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.